Literature DB >> 27352857

Reirradiation of Pediatric Tumors Using Hypofractionated Stereotactic Radiotherapy.

Melis Gultekin1, Mustafa Cengiz1, Duygu Sezen2, Faruk Zorlu1, Ferah Yildiz1, Gozde Yazici1, Pervin Hurmuz1, Gokhan Ozyigit1, Fadil Akyol1, Murat Gurkaynak1.   

Abstract

BACKGROUND: This study aimed to evaluate the efficacy and safety of hypofractionated stereotactic radiotherapy for reirradiation of recurrent pediatric tumors. METHODS AND MATERIALS: The study included 23 pediatric patients who were reirradiated using hypofractionated stereotactic radiotherapy in the radiation oncology department between January 2008 and November 2013. In total, 33 tumors were treated-27 (82%) cranial and 6 (18%) extracranial. Hypofractionated stereotactic radiotherapy was administered due to recurrent disease in 31 (94%) tumors and residual disease in 2 (6%) tumors. The median total dose was 25 Gy (range: 15-40 Gy), and the median follow-up was 20 months (range: 2-68 months).
RESULTS: The 1-year and 2-year local control rates in the entire study population were 42% and 31%, respectively. The median local control time was 11 months (range: 0-54 months) following hypofractionated stereotactic radiotherapy. The patients with tumor response after hypofractionated stereotactic radiotherapy had significantly longer local control than the patients with post-hypofractionated stereotactic radiotherapy tumor progression (21 vs 3 months, P < .001). Tumor volume <1.58 cm3 was correlated (not significantly) with better local control (23 vs 7 months, P = .064).
CONCLUSION: Reirradiation of pediatric tumors using hypofractionated stereotactic radiotherapy is a safe and effective therapeutic approach. This treatment modality should be considered as a treatment option in selected pediatric patients.

Entities:  

Keywords:  hypofractionation; pediatric tumors; reirradiation; stereotactic body radiotherapy; stereotactic radiotherapy

Mesh:

Year:  2016        PMID: 27352857      PMCID: PMC5616030          DOI: 10.1177/1533034616655952

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  33 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

Review 2.  Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy in the management of intracranial ependymoma.

Authors:  Simon S Lo; Eric L Chang; Andrew E Sloan
Journal:  Expert Rev Neurother       Date:  2006-04       Impact factor: 4.618

Review 3.  The safety and efficacy of robotic image-guided radiosurgery system treatment for intra- and extracranial lesions: a systematic review of the literature.

Authors:  Nieves Calcerrada Díaz-Santos; Juan Antonio Blasco Amaro; Gloria Ariza Cardiel; Elena Andradas Aragonés
Journal:  Radiother Oncol       Date:  2008-08-28       Impact factor: 6.280

4.  Stereotactic radiosurgery in pediatric patients.

Authors:  B E Weprin; W A Hall; K H Cho; P W Sperduto; B J Gerbi; C Moertel
Journal:  Pediatr Neurol       Date:  1996-10       Impact factor: 3.372

5.  Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer.

Authors:  Frank J Lagerwaard; Cornelis J A Haasbeek; Egbert F Smit; Ben J Slotman; S Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

6.  Maximally safe resection followed by hypofractionated re-irradiation for locally recurrent ependymoma in children.

Authors:  Arthur K Liu; Nicholas K Foreman; Laurie E Gaspar; Elizabeth Trinidad; Michael H Handler
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

7.  Tumor response to radiotherapy regulated by endothelial cell apoptosis.

Authors:  Monica Garcia-Barros; Francois Paris; Carlos Cordon-Cardo; David Lyden; Shahin Rafii; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

8.  Stereotactic radiation therapy with chemotherapy in the management of recurrent medulloblastomas.

Authors:  Masamitsu Abe; Sunao Tokumaru; Kazuo Tabuchi; Yoshihisa Kida; Masashi Takagi; Junichi Imamura
Journal:  Pediatr Neurosurg       Date:  2006       Impact factor: 1.162

Review 9.  Radiation response of the central nervous system.

Authors:  T E Schultheiss; L E Kun; K K Ang; L C Stephens
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

Review 10.  Normal tissue toxicity after small field hypofractionated stereotactic body radiation.

Authors:  Michael T Milano; Louis S Constine; Paul Okunieff
Journal:  Radiat Oncol       Date:  2008-10-31       Impact factor: 3.481

View more
  3 in total

1.  Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience.

Authors:  Derek S Tsang; Nasim Sarhan; Vijay Ramaswamy; Liana Nobre; Ryan Yee; Michael D Taylor; Cynthia Hawkins; Ute Bartels; Annie Huang; Uri Tabori; David C Hodgson; Eric Bouffet; Normand Laperriere
Journal:  J Neurooncol       Date:  2019-08-29       Impact factor: 4.130

2.  Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults.

Authors:  Christopher L Tinkle; Charu Singh; Shane Lloyd; Yian Guo; Yimei Li; Alberto S Pappo; Steven G DuBois; John T Lucas; Daphne A Haas-Kogan; Stephanie A Terezakis; Steve E Braunstein; Matthew J Krasin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-11-28       Impact factor: 7.038

Review 3.  Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment.

Authors:  Rebecca M Hill; Sabine L A Plasschaert; Beate Timmermann; Christelle Dufour; Kristian Aquilina; Shivaram Avula; Laura Donovan; Maarten Lequin; Torsten Pietsch; Ulrich Thomale; Stephan Tippelt; Pieter Wesseling; Stefan Rutkowski; Steven C Clifford; Stefan M Pfister; Simon Bailey; Gudrun Fleischhack
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.